Immuno-Oncology | Specialty

Dr. Subramanian on Ongoing Trials for Patients With Nonsquamous NSCLC

January 16th 2019

Janakiraman Subramanian, MD, medical oncologist, director of Thoracic Oncology, Center for Precision Medicine, Saint Luke’s Cancer Institute, discusses ongoing trials evaluating the use of immunotherapy in patients with nonsquamous non–small cell lung cancer (NSCLC).

Grivas Discusses Developments in Bladder Cancer

January 16th 2019

Petros Grivas, MD, PhD, discusses the rapidly evolving field of locally advanced and metastatic bladder cancer.

Dr. Wright Discusses Immunotherapy in Bladder Cancer

January 15th 2019

Jonathan L. Wright, MD, MS, FACS, medical director, Urology Clinic, University of Washington Medical Center, affiliate investigator, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, discusses immunotherapy in bladder cancer.

Nivolumab/Ipilimumab Combo Approved in Europe for Frontline RCC

January 15th 2019

The European Commission has approved nivolumab combined with low-dose ipilimumab as a frontline treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma.

Immunotherapy/VEGF Inhibitor Combos to Define Frontline Standard in mRCC

January 14th 2019

Sumanta K. Pal, highlights the different combination regimens that are making headlines in the treatment of patients with metastatic renal cell carcinoma.

Dr. Figlin on Considerations for Combining TKIs and Immunotherapy in RCC

January 10th 2019

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses considerations when combining TKIs and immunotherapy agents in the management of advanced renal cell carcinoma.

Checkpoint Inhibitors Herald New Era in Urothelial Cancer

January 9th 2019

Immune checkpoint inhibitors, with their favorable safety and antitumor activity profiles, have heralded a new era in urothelial carcinoma treatment.

Treatment Breakthroughs Advance Care Across Heterogeneous NSCLC Population

January 8th 2019

Kwok-Kin Wong, MD, PhD, discusses updates in non–small cell lung cancer and the importance of enrolling patients in clinical trials to further progress the field.

Bellmunt Addresses Immunotherapy Advances, Challenges in Bladder Cancer

January 8th 2019

Joaquim Bellmunt, MD, PhD, provides insight on how to navigate the complex treatment paradigm of metastatic bladder cancer.

Closer Study Required of Immunological Differences Between Sexes

January 7th 2019

Study results demonstrate that men and women differ in their immunological responses to foreign and self-antigens.

Dr. Perez-Soler on Immunotherapy Advances in SCLC

January 7th 2019

Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, discusses recent advances in immunotherapy for the treatment of patients with small cell lung cancer.

Finding a Place for Stimulatory Immune Checkpoint Antibodies

January 7th 2019

When it works, immunotherapy can dramatically outperform standard of care—for some cancer types, in ways thought unattainable a decade ago.

Dr. Bellmunt Highlights Immunotherapy Options in Bladder Cancer

January 4th 2019

Joaquim Bellmunt, MD, PhD, genitourinary oncologist, Beth Israel Deaconess Medical Center, associate professor of medicine, Harvard Medical School, differentiates between immunotherapy options available for the treatment of patients with in bladder cancer.

Forde Forecasts Future Use of Immunotherapy in Early-Stage NSCLC

January 4th 2019

Patrick M. Forde, MBBCh, discusses the future of immunotherapy in early-stage non–small cell lung cancer.

Expert Reflects on 2018 Lung Cancer Advancements

January 2nd 2019

Joshua K. Sabari, MD, reflects on the rapidly advancing landscape of lung cancer.

Immunotherapy Advances SCLC Treatment Landscape

December 27th 2018

The new standard of care for the frontline treatment of patients with extensive-stage small cell lung cancer should be atezolizumab and chemotherapy, based on results from the IMpower133 trial.

Biomarker Hunt Focuses on Predicting Immunotherapy Adverse Events

December 26th 2018

Although the need for biomarkers of immunotherapy response has generated much attention, investigators also are pursuing mechanisms for distinguishing which patients will experience adverse effects from these therapies.

FDA Delays Decision on Frontline Pembrolizumab sBLA in NSCLC

December 21st 2018

The FDA has extended the review period for a supplemental biologics license application for single-agent pembrolizumab for the frontline treatment of patients with locally advanced or metastatic nonsquamous or squamous non–small cell lung cancer with a PD-L1 expression level of ≥1% and no EGFR or ALK genomic tumor aberrations.

Dr. Overman on Next Steps With Immunotherapy in mCRC

December 20th 2018

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses next steps with immunotherapy in the treatment of patients with metastatic colorectal cancer.

Dr. Brahmer on Biomarkers for Immune Response in NSCLC

December 18th 2018

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses biomarkers for immune response in non–small cell lung cancer.